CASI Pharmaceuticals Approved for CID-103 Clinical Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 15 2026
0mins
CASI Pharmaceuticals announced that China National Medical Products Administration has approved a Clinical Trial Application to conduct a Phase 1 /2 clinical trial for CID-103 in adults with chronic active renal allograft antibody-mediated rejection. The Phase 1 / 2 clinical trial is a dose-ranging and safety study evaluating the tolerability and efficacy of CID-103 in patients with renal allograft AMR.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
